Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients

Abstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients bo...

Full description

Bibliographic Details
Main Authors: Kristina Sandgren, Lennart Johansson, Jan Axelsson, Joakim Jonsson, Mattias Ögren, Margareta Ögren, Martin Andersson, Sara Strandberg, Tufve Nyholm, Katrine Riklund, Anders Widmark
Format: Article
Language:English
Published: SpringerOpen 2019-01-01
Series:EJNMMI Physics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40658-018-0239-2
id doaj-b79978a90bfb4852af48633cdb9d1498
record_format Article
spelling doaj-b79978a90bfb4852af48633cdb9d14982020-11-24T21:21:17ZengSpringerOpenEJNMMI Physics2197-73642019-01-016111110.1186/s40658-018-0239-2Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patientsKristina Sandgren0Lennart Johansson1Jan Axelsson2Joakim Jonsson3Mattias Ögren4Margareta Ögren5Martin Andersson6Sara Strandberg7Tufve Nyholm8Katrine Riklund9Anders Widmark10Department of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Medical Radiation Physics, ITM, Lund UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityAbstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [68Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. Methods Six low-risk prostate cancer patients were injected with 133–178 MBq [68Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. Results [68Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [68Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). Conclusion The effective dose for [68Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose.http://link.springer.com/article/10.1186/s40658-018-0239-2Radiation dosimetry[68Ga]PSMA-11PSMAPET-tracerProstate cancerAbsorbed dose and effective dose
collection DOAJ
language English
format Article
sources DOAJ
author Kristina Sandgren
Lennart Johansson
Jan Axelsson
Joakim Jonsson
Mattias Ögren
Margareta Ögren
Martin Andersson
Sara Strandberg
Tufve Nyholm
Katrine Riklund
Anders Widmark
spellingShingle Kristina Sandgren
Lennart Johansson
Jan Axelsson
Joakim Jonsson
Mattias Ögren
Margareta Ögren
Martin Andersson
Sara Strandberg
Tufve Nyholm
Katrine Riklund
Anders Widmark
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
EJNMMI Physics
Radiation dosimetry
[68Ga]PSMA-11
PSMA
PET-tracer
Prostate cancer
Absorbed dose and effective dose
author_facet Kristina Sandgren
Lennart Johansson
Jan Axelsson
Joakim Jonsson
Mattias Ögren
Margareta Ögren
Martin Andersson
Sara Strandberg
Tufve Nyholm
Katrine Riklund
Anders Widmark
author_sort Kristina Sandgren
title Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
title_short Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
title_full Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
title_fullStr Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
title_full_unstemmed Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
title_sort radiation dosimetry of [68ga]psma-11 in low-risk prostate cancer patients
publisher SpringerOpen
series EJNMMI Physics
issn 2197-7364
publishDate 2019-01-01
description Abstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [68Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. Methods Six low-risk prostate cancer patients were injected with 133–178 MBq [68Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. Results [68Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [68Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). Conclusion The effective dose for [68Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose.
topic Radiation dosimetry
[68Ga]PSMA-11
PSMA
PET-tracer
Prostate cancer
Absorbed dose and effective dose
url http://link.springer.com/article/10.1186/s40658-018-0239-2
work_keys_str_mv AT kristinasandgren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT lennartjohansson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT janaxelsson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT joakimjonsson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT mattiasogren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT margaretaogren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT martinandersson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT sarastrandberg radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT tufvenyholm radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT katrineriklund radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
AT anderswidmark radiationdosimetryof68gapsma11inlowriskprostatecancerpatients
_version_ 1725999875579969536